Last reviewed · How we verify
ZN-c3 (zn-c3)
ZN-c3 tablet by mouth, in combination with encorafenib
Unable to provide summary: ZN-c3 lacks FDA mechanism text and approved indication data in the provided information. Please verify drug name and provide complete FDA prescribing information for accurate clinical summary.
At a glance
| Generic name | zn-c3 |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | ZN-c3 tablet by mouth, in combination with encorafenib |
| Therapeutic area | Oncology |
| Phase | discontinued |
Approved indications
Pipeline indications
- Metastatic Colorectal Cancer — discontinued
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ZN-c3 CI brief — competitive landscape report
- ZN-c3 updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI